^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

INB-200

i
Other names: INB-200, Gamma-Delta T Cell Therapy , Gamma-Delta (γδ)T Cell Therapy , DRI cell therapy, DeltEx Drug Resistant Immunotherapy, MGMT-gene modified gdT cells, DeltEx DRI, INB 200, INB200
Associations
Trials
Company:
IN8bio
Drug class:
γδ TCR modulator
Associations
Trials
3ms
Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma. (PubMed, Cancers (Basel))
Glioblastoma (GBM) is an immunologically cold tumor, but several immunotherapy-based strategies show promise, including the administration of ex vivo expanded and activated cytotoxic gamma delta T cells. Gamma delta T cell-mediated cytotoxicity at a 10:1 effector-to-target ratio was significantly increased upon pretreatment of cells derived from a GBM PDX with TMZ and niraparib in comparison to the control or either drug alone. Together, these data demonstrate that the combination of PARP inhibition, DNA alkylation, and gamma delta T cell therapy has the potential for the treatment of GBM.
Journal • PARP Biomarker • IO biomarker
|
ULBP1 (UL16 Binding Protein 1)
|
temozolomide • Zejula (niraparib) • INB-200
9ms
Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions. (PubMed, Front Immunol)
We then validated a therapeutic system that we termed Drug Resistance Immunotherapy (DRI) that combines a standard regimen of TMZ concomitantly with simultaneous intracranial infusion of TMZ-resistant γδ T cells in a first-in-human Phase I clinical trial (NCT04165941). This manuscript will discuss DRI as a rational therapeutic approach to newly diagnosed GBM and the importance of repeated administration of DRI in combination with the standard-of-care Stupp regimen in patients with stable minimal residual disease.
Journal • IO biomarker
|
NKG2D (killer cell lectin like receptor K1)
|
temozolomide • INB-200
10ms
Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
P1, N=21, Active, not recruiting, University of Alabama at Birmingham | Recruiting --> Active, not recruiting | N=12 --> 21 | Trial primary completion date: Jan 2024 --> Dec 2024
Enrollment closed • Enrollment change • Trial primary completion date
|
temozolomide • INB-200
1year
INB-200: Phase 1 Study of Gene Modified Autologous Gamma-delta (γδ) T Cells in Newly Diagnosed Glioblastoma Multiforme (GBM) Patients Receiving Maintenance Temozolomide (TMZ) (SNO 2023)
γδ T cells successfully infused with peripheral TMZ-based lymphodepletion evidenced with near or below normal range T, B, and NK subsets for up to 1 year. DRI T cells have manageable toxicity with encouraging trend in PFS with enriched γδ T cell remaining despite peripheral lymphodepletion.
Clinical • P1 data
|
MGMT (6-O-methylguanine-DNA methyltransferase) • NKG2D (killer cell lectin like receptor K1)
|
IDH wild-type • MGMT expression
|
temozolomide • INB-200
1year
INB-400 Phase 1b/2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells in Combination With Maintenance Temozolomide Recurrent or Newly Diagnosed Glioblastoma (SNO 2023)
INB-200, a Phase 1 trial, demonstrated the safety and efficacy of autologously (auto) derived genetically modified drug resistant immunotherapy (DRI) gd T cells combined with maintenance temozolomide (TMZ) to treat newly diagnosed (ND) patients with GBM. Allo arm patients must have a haploidentical donor. Fifteen US centers will conduct study.
Clinical • P1/2 data • Combination therapy
|
NKG2D (killer cell lectin like receptor K1)
|
IDH wild-type
|
temozolomide • INB-200
3years
Enhancing Glioblastoma Cell Stress Response to Improve Gamma Delta T-cell Immunotherapy (SNO 2021)
The cellular stress induced by Temozolomide (TMZ) increases innate immune ligands, which could be exploited to promote immune recognition...To further promote immune recognition, we sought to augment the TMZ-induced stress response by exploring the combination of DNA alkylation with either PARP (Niraparib) or ATM Kinase inhibition (AZD1390)...We are currently determining whether these combinatorial treatments improve gamma delta T-cell cytotoxicity against GBM cells and in vivo tumor models. Taken together, our data suggest that enhancing cell stress responses induced by chemotherapies may permit novel immunotherapy therapeutic interventions for brain tumor patients.
PARP Biomarker • IO biomarker
|
NKG2D (killer cell lectin like receptor K1)
|
temozolomide • Zejula (niraparib) • AZD1390 • INB-200